Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF as well as how a multimodal approach used in HF with reduced EF can be adapted for managing these conditions.

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

Now Viewing

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

What additional benefits does adding finerenone offer when combined with sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF)?
When considering the multimodal approach for the treatment of HF with reduced EF, how can that strategy now be implemented for the management of HFmrEF and HFpEF?
What results were presented?